Robert Canarick - 21 May 2025 Form 4 Insider Report for INTEGRATED BIOPHARMA INC (INBP)

Reporting relationship: Director
Issuer ticker: INBP
Reported as of: 21 May 2025
Net transaction value: +$15,750
SEC form: 4
Accepted by SEC: 22 May 2025, 17:09:20 UTC
Prior SEC filing: 08 Aug 2024
Next SEC filing: 20 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Robert Canarick

Key filing fact

Robert Canarick filed Form 4 for INTEGRATED BIOPHARMA INC (INBP) on 22 May 2025.

Key facts

This page summarizes Robert Canarick's Form 4 filing for INTEGRATED BIOPHARMA INC (INBP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 May 2025, 17:09.

Change

Previous filing in this sequence was filed on 08 Aug 2024.
Current net transaction value: +$15,750.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001382218 Primary reporting owner

Canarick Robert

Relationship: Director
Address: C/O INTEGRATED BIOPHARMA, INC., 201 ROUTE 22, HILLSIDE
Signature: /s/ Robert Canarick
Signature date: 22 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INBP transaction

Common Stock

Award

Transaction value: $15,750
Shares: +175,000
Change %: +295%
Price: $0.0900
Shares after: 234,233
Date: 21 May 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INBP transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -175,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 21 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 175,000
Exercise price: $0.0900
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

175,000 common stock shares acquired upon exercise of stock option grant dated June 2, 2015.

Footnote F2

75% of the options became exercisable on June 2, 2015 with 25% becoming exercisable in twelve (12) equal monthly installments beginning on July 2, 2015.